Feed AMGN
AM

Amgen

AMGN · NASDAQ

$414.61 +1.56% (+$6.36)
1M -4.12%
Market Cap $212.2B
P/E Ratio 24.27x
Div. Yield 2.53%
ROE 89.32%

Bulios Fair Price

$424.2

2.3% upside

Current Price

$414.61

Undervalued Fair Value Overvalued

According to Bulios Fair Price, AMGN is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Strong
8/9
Valuation
49 /100
Fair
P/E 24.27x
EV/EBITDA 15.48x
P/S 5.57x
Growth
53 /100
Stable
EPS growth 5.52%
Rev. growth 11.76%
FCF growth 2.67%
Profitability
100 /100
Strong
Gross margin 72.65%
Net margin 22.93%
Op. margin 33.18%
Quality
78 /100
Excellent
ROIC 14.22%
ROE 89.32%
ROA 9.14%
Debt
37 /100
Moderate
Debt/Equity 4.90x
Current ratio 1.37x
Int. coverage 4.86x
Stability
65 /100
Moderate
Beta 0.43x
Rev. volatility 5.98%
EPS volatility 65.02%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about AMGN
Online

About the company

Amgen Inc. is an American biotechnology company specializing in research, development, and manufacturing of biologic medicines. The company focuses on innovative therapeutic treatments for various diseases, including cancer, cardiovascular conditions, arthritis, and other serious illnesses. Amgen has developed a range of successful drugs that have transformed the lives of patients worldwide. The company also invests in research for new drugs and treatment approaches to better address current and future healthcare challenges. Amgen collaborates with physicians, scientists, and other experts to improve healthcare and develop new therapeutic options. Amgen Inc. (AMGN) shares are an interesting choice for investors who follow the biotechnology sector and seek investment opportunities in a reputable company that brings innovative therapeutic treatments for serious diseases.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Robert A. Bradway

Employees

31,500

Headquarters

Thousand Oaks

Upcoming events

03 NOV

Earnings

Upcoming earnings report

37d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.